Cyto-Facto
$8.3M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Cyto-Facto is currently valued at N/A as of June 13, 2025. The company has raised a total of $18.3M in funding.
Investment Perspective
Cyto-Facto's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Cyto-Facto Worth in 2025?
As of 2025, Cyto-Facto is valued at N/A, based on the company's Early Stage VC funding round in June 13, 2025. This valuation positions Cyto-Facto as one of the leading private companies in the sector.
Cyto-Facto Valuation History
Cyto-Facto's funding history demonstrates steady growth and investor confidence.
How Cyto-Facto Valuation is Determined
Private company valuations like Cyto-Facto's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Cyto-Facto Valuation FAQs
Is Cyto-Facto profitable?
Cyto-Facto has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Cyto-Facto's valuation compare to competitors?
Cyto-Facto is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Cyto-Facto IPO?
Cyto-Facto has not announced plans for an initial public offering. Until an IPO, investors can access Cyto-Facto shares through secondary market platforms.